A CRISPR-Cas Cure for HIV/AIDS
Human immunodeficiency virus (HIV) infections and HIV-induced acquired immunodeficiency syndrome (AIDS) continue to represent a global health burden. There is currently no effective vaccine, nor any cure, for HIV infections; existing antiretroviral therapy can suppress viral replication, but only as...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-01-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/24/2/1563 |
| _version_ | 1797441160140029952 |
|---|---|
| author | Mouraya Hussein Mariano A. Molina Ben Berkhout Elena Herrera-Carrillo |
| author_facet | Mouraya Hussein Mariano A. Molina Ben Berkhout Elena Herrera-Carrillo |
| author_sort | Mouraya Hussein |
| collection | DOAJ |
| description | Human immunodeficiency virus (HIV) infections and HIV-induced acquired immunodeficiency syndrome (AIDS) continue to represent a global health burden. There is currently no effective vaccine, nor any cure, for HIV infections; existing antiretroviral therapy can suppress viral replication, but only as long as antiviral drugs are taken. HIV infects cells of the host immune system, and it can establish a long-lived viral reservoir, which can be targeted and edited through gene therapy. Gene editing platforms based on the clustered regularly interspaced palindromic repeat-Cas system (CRISPR-Cas) have been recognized as promising tools in the development of gene therapies for HIV infections. In this review, we evaluate the current landscape of CRISPR-Cas-based therapies against HIV, with an emphasis on the infection biology of the virus as well as the activity of host restriction factors. We discuss the potential of a combined CRISPR-Cas approach that targets host and viral genes to activate antiviral host factors and inhibit viral replication simultaneously. Lastly, we focus on the challenges and potential solutions of CRISPR-Cas gene editing approaches in achieving an HIV cure. |
| first_indexed | 2024-03-09T12:19:58Z |
| format | Article |
| id | doaj.art-8bd43bd048ad4d74846d0dd5403e8db7 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-09T12:19:58Z |
| publishDate | 2023-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-8bd43bd048ad4d74846d0dd5403e8db72023-11-30T22:42:20ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672023-01-01242156310.3390/ijms24021563A CRISPR-Cas Cure for HIV/AIDSMouraya Hussein0Mariano A. Molina1Ben Berkhout2Elena Herrera-Carrillo3Laboratory of Experimental Virology, Department of Medical Microbiology, Amsterdam UMC, Academic Medical Center, University of Amsterdam, 1105 AZ Amsterdam, The NetherlandsLaboratory of Experimental Virology, Department of Medical Microbiology, Amsterdam UMC, Academic Medical Center, University of Amsterdam, 1105 AZ Amsterdam, The NetherlandsLaboratory of Experimental Virology, Department of Medical Microbiology, Amsterdam UMC, Academic Medical Center, University of Amsterdam, 1105 AZ Amsterdam, The NetherlandsLaboratory of Experimental Virology, Department of Medical Microbiology, Amsterdam UMC, Academic Medical Center, University of Amsterdam, 1105 AZ Amsterdam, The NetherlandsHuman immunodeficiency virus (HIV) infections and HIV-induced acquired immunodeficiency syndrome (AIDS) continue to represent a global health burden. There is currently no effective vaccine, nor any cure, for HIV infections; existing antiretroviral therapy can suppress viral replication, but only as long as antiviral drugs are taken. HIV infects cells of the host immune system, and it can establish a long-lived viral reservoir, which can be targeted and edited through gene therapy. Gene editing platforms based on the clustered regularly interspaced palindromic repeat-Cas system (CRISPR-Cas) have been recognized as promising tools in the development of gene therapies for HIV infections. In this review, we evaluate the current landscape of CRISPR-Cas-based therapies against HIV, with an emphasis on the infection biology of the virus as well as the activity of host restriction factors. We discuss the potential of a combined CRISPR-Cas approach that targets host and viral genes to activate antiviral host factors and inhibit viral replication simultaneously. Lastly, we focus on the challenges and potential solutions of CRISPR-Cas gene editing approaches in achieving an HIV cure.https://www.mdpi.com/1422-0067/24/2/1563CRISPR-CasHIVviral geneshost factors |
| spellingShingle | Mouraya Hussein Mariano A. Molina Ben Berkhout Elena Herrera-Carrillo A CRISPR-Cas Cure for HIV/AIDS International Journal of Molecular Sciences CRISPR-Cas HIV viral genes host factors |
| title | A CRISPR-Cas Cure for HIV/AIDS |
| title_full | A CRISPR-Cas Cure for HIV/AIDS |
| title_fullStr | A CRISPR-Cas Cure for HIV/AIDS |
| title_full_unstemmed | A CRISPR-Cas Cure for HIV/AIDS |
| title_short | A CRISPR-Cas Cure for HIV/AIDS |
| title_sort | crispr cas cure for hiv aids |
| topic | CRISPR-Cas HIV viral genes host factors |
| url | https://www.mdpi.com/1422-0067/24/2/1563 |
| work_keys_str_mv | AT mourayahussein acrisprcascureforhivaids AT marianoamolina acrisprcascureforhivaids AT benberkhout acrisprcascureforhivaids AT elenaherreracarrillo acrisprcascureforhivaids AT mourayahussein crisprcascureforhivaids AT marianoamolina crisprcascureforhivaids AT benberkhout crisprcascureforhivaids AT elenaherreracarrillo crisprcascureforhivaids |